293 related articles for article (PubMed ID: 17064066)
1. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Plé PA; Green TP; Hennequin LF; Curwen J; Fennell M; Allen J; Lambert-Van Der Brempt C; Costello G
J Med Chem; 2004 Feb; 47(4):871-87. PubMed ID: 14761189
[TBL] [Abstract][Full Text] [Related]
3. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
[TBL] [Abstract][Full Text] [Related]
4. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
[TBL] [Abstract][Full Text] [Related]
5. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
6. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
7. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
Ballard P; Bradbury RH; Hennequin LF; Hickinson DM; Johnson PD; Kettle JG; Klinowska T; Morgentin R; Ogilvie DJ; Olivier A
Bioorg Med Chem Lett; 2005 Oct; 15(19):4226-9. PubMed ID: 16055332
[TBL] [Abstract][Full Text] [Related]
8. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Hennequin LF; Stokes ES; Thomas AP; Johnstone C; Plé PA; Ogilvie DJ; Dukes M; Wedge SR; Kendrew J; Curwen JO
J Med Chem; 2002 Mar; 45(6):1300-12. PubMed ID: 11881999
[TBL] [Abstract][Full Text] [Related]
9. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
Noronha G; Barrett K; Boccia A; Brodhag T; Cao J; Chow CP; Dneprovskaia E; Doukas J; Fine R; Gong X; Gritzen C; Gu H; Hanna E; Hood JD; Hu S; Kang X; Key J; Klebansky B; Kousba A; Li G; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Shi F; Soll R; Splittgerber U; Stoughton S; Tang S; Yee S; Zeng B; Zhao N; Zhu H
Bioorg Med Chem Lett; 2007 Feb; 17(3):602-8. PubMed ID: 17113292
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.
Bardelle C; Barlaam B; Brooks N; Coleman T; Cross D; Ducray R; Green I; Brempt CL; Olivier A; Read J
Bioorg Med Chem Lett; 2010 Nov; 20(21):6242-5. PubMed ID: 20850301
[TBL] [Abstract][Full Text] [Related]
11. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
12. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
[TBL] [Abstract][Full Text] [Related]
13. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
14. New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors.
Barlaam B; Fennell M; Germain H; Green T; Hennequin L; Morgentin R; Olivier A; Plé P; Vautier M; Costello G
Bioorg Med Chem Lett; 2005 Dec; 15(24):5446-9. PubMed ID: 16203139
[TBL] [Abstract][Full Text] [Related]
15. Quantification of focal adhesion kinase activation loop phosphorylation as a biomarker of Src activity.
Ciccimaro E; Hanks SK; Blair IA
Mol Pharmacol; 2009 Mar; 75(3):658-66. PubMed ID: 19098120
[TBL] [Abstract][Full Text] [Related]
16. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
17. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Cha MY; Lee KO; Kim JW; Lee CG; Song JY; Kim YH; Lee GS; Park SB; Kim MS
J Med Chem; 2009 Nov; 52(21):6880-8. PubMed ID: 19888761
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
Lombardo LJ; Lee FY; Chen P; Norris D; Barrish JC; Behnia K; Castaneda S; Cornelius LA; Das J; Doweyko AM; Fairchild C; Hunt JT; Inigo I; Johnston K; Kamath A; Kan D; Klei H; Marathe P; Pang S; Peterson R; Pitt S; Schieven GL; Schmidt RJ; Tokarski J; Wen ML; Wityak J; Borzilleri RM
J Med Chem; 2004 Dec; 47(27):6658-61. PubMed ID: 15615512
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines.
Wang YD; Miller K; Boschelli DH; Ye F; Wu B; Floyd MB; Powell DW; Wissner A; Weber JM; Boschelli F
Bioorg Med Chem Lett; 2000 Nov; 10(21):2477-80. PubMed ID: 11078204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
